PREDNOS 2 is a national multicentre double blind randomised controlled trial of short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome (SSNS).
Full Title: Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome
Short Title: PREDNOS 2 study
Aim of the study: To evaluate the effectiveness of a six day course of daily prednisoline therapy at the time of URTI in reducing the development of subsequent nephrotic syndrome relapse in children with relapsing SSNS.
Study design: Double blind randomised controlled trial (RCT).
Sample size: 300 patients will be recruited into the study (150 in each arm) over a 2 year period.
Study Duration: The accrual period is for 2 years and all patients will be followed up for 12 months. The end of trial will be 6 months after the last data capture. The last data capture will be 12 months following recruitment of the last patient. The total study duration is 4 years.
Timeframes: NIHR HTA grant start date: 1st October 2012. Trial set up will take place in 6 months, recruitment will take 24 months, all patients will be followed up for 12 months and 6 months has been allocated for data analysis and report writing. The first patient was randomised on 19th March 2013.
PREDNOS 2 Protocol V1.3 (29th April 2015)
PREDNOS 2 Online Randomisation and Data Entry
Contact the PREDNOS 2 trial team
Chief Investigator: Professor Nicholas Webb
Trial Co-Sponsor: Central Manchester University Hospitals NHS Foundation Trust and University of Birmingham (Ref: RG_12-188)
Funding: National Institute for Health Research Health Technology Assessment programme (NIHR HTA) Ref: 11/129/261
EudraCT Number: 2012-003476-39
MHTA CTA: 21761/0281/001-0001 (28th November 2012)
Research Ethics Committee: North West GM Central (Ref: 12/NW/0766) (4th December 2012)
NIHR CRN Study ID: 13410